Michael Halstead

Filings by Michael Halstead span 2 companies, the busiest being Intra-Cellular Therapies, Inc. and Cybin Inc. The record holds 20 filings, for trades running from 21 December 2021 to 21 September 2026.

Both buying and selling appear: 1 purchase worth €1.2M, against 1 sale worth €784k. The net balance comes to €389k on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 3 share grants and 14 option exercises. Since January 2026: 1 purchase and no sales on the market.

On 21 September 2026 came the latest disclosure, an open-market purchase for €1.2M in Cybin Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.